Search - tctmd.com

Displaying 101 - 120 of 161

Sort: Relevancy | Date

Dabigatran Discontinuation Rate Highest Early After Treatment Begins

News Daily News

Dabigatran Discontinuation Rate Highest Early After Treatment Begins

November 12, 2019

New-Onset A-fib Tied to Particularly Poor Outcomes After TAVR

News Daily News

New-Onset A-fib Tied to Particularly Poor Outcomes After TAVR

October 18, 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

News Conference News ESC 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

September 11, 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

News Conference News ESC 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

September 03, 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

News Conference News ESC 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

September 02, 2019

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

News Daily News

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

August 21, 2019

‘Manageable’ Stroke Risk Seen With Electrical LAA Isolation

News Daily News

‘Manageable’ Stroke Risk Seen With Electrical LAA Isolation

August 19, 2019

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

News Daily News

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

Michael O'Riordan

July 03, 2019

Potential Warning Signs Seen for NOAC Use After TAVR

News Daily News

Potential Warning Signs Seen for NOAC Use After TAVR

June 12, 2019

Antithrombotic Use, Risk Perception, Varies Widely for PCI Patients With A-fib

News Conference News SCAI 2019

Antithrombotic Use, Risk Perception, Varies Widely for PCI Patients With A-fib

Yael L. Maxwell

May 24, 2019

Even in the DOAC Era, Women Less Likely Than Men to Receive Anticoagulation for A-fib

News Conference News HRS 2019

Even in the DOAC Era, Women Less Likely Than Men to Receive Anticoagulation for A-fib

May 17, 2019

ERADICATE-AF: Could Add-on Renal Denervation Give A-fib Ablation a Boost?

News Conference News HRS 2019

ERADICATE-AF: Could Add-on Renal Denervation Give A-fib Ablation a Boost?

May 10, 2019

CABANA Results Largely Generalizable to Real-World A-fib Patients

News Daily News

CABANA Results Largely Generalizable to Real-World A-fib Patients

May 03, 2019

Thromboembolic Risks High in Patients With A-fib, Valvular Disease

News Conference News EHRA 2019

Thromboembolic Risks High in Patients With A-fib, Valvular Disease

March 25, 2019

Streamlined Procedure Maintains Benefits of Cryoablation Over Drugs for Paroxysmal A-fib

News Conference News EHRA 2019

Streamlined Procedure Maintains Benefits of Cryoablation Over Drugs for Paroxysmal A-fib

March 20, 2019

DOACs in Patients With Mitral Stenosis and A-fib: Analysis Suggests a Benefit

News Daily News

DOACs in Patients With Mitral Stenosis and A-fib: Analysis Suggests a Benefit

March 12, 2019

Continuing Anticoagulation During TAVR in A-fib Patients May Be Safe, Study Suggests

News Daily News

Continuing Anticoagulation During TAVR in A-fib Patients May Be Safe, Study Suggests

January 09, 2019

Stroke Risk Increases Over Time in Many Patients With A-fib

News Daily News

Stroke Risk Increases Over Time in Many Patients With A-fib

January 08, 2019

High Risk of Major Bleeding Observed in Danish A-fib Population on Triple, Dual Antithrombotic Therapy

News Daily News

High Risk of Major Bleeding Observed in Danish A-fib Population on Triple, Dual Antithrombotic Therapy

Yael L. Maxwell

December 13, 2018

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

News Features

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

October 22, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.